Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation, Oncology, and Cell Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD62L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD62L ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). HEK293 expressed for native glycosylation. Sequence Verified. |
View CD62L Products |
| Gene Delivery | CD62L Promise-ORF / Lentivirus Full-length ORF (WT or cleavage-resistant mutants) for stable cell line construction. |
View CD62L Products |
| Benchmark Ab | Anti-CD62L Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CD62L Products |
| Validator | CD62L siRNA Set Target-specific knockdown verification pool. |
View CD62L Products |
| Related Target A | CD62P (P-selectin) Subfamily homolog for off-target selectivity and cross-reactivity screening. |
View CD62P Products |
| Related Target B | CD62E (E-selectin) Subfamily homolog for comprehensive selectin panel profiling. |
View CD62E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding-induced assay instability | Cleavage-resistant CD62L mutant constructs (ADAM17-resistant) available for stable cell-based assays. |
| Subfamily cross-reactivity (CD62P/CD62E) | High-purity recombinant CD62P and CD62E proteins strictly verified by mass spectrometry for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for target knockdown and specificity verification. |
Live CD62L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD62L therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to cell therapy optimization and bispecific immune-engagers. CD62L (L-selectin) is a critical homing receptor mediating leukocyte rolling on high endothelial venules. In oncology, maintaining high CD62L expression on CAR-T and TCR-T cells is strongly correlated with enhanced stemness, prolonged in vivo persistence, and superior anti-tumor efficacy. As first-generation therapies reach the clinic, the next wave of R&D is targeting the prevention of CD62L shedding (mediated by ADAM17) and developing bispecific agents that leverage CD62L for targeted leukocyte trafficking.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cell Therapy (CAR-T/TCR-T) | Novartis, Gilead, Academic Institutions | Hematological Malignancies, Solid Tumors | Shedding Prevention & Homing Assay (Need cleavage-resistant CD62L lentivirus) |
| Monoclonal Antibodies | Academic Medical Centers, Biotech Startups | Autoimmune & Inflammatory Diseases | Blocking & Binding Kinetics (Need HEK293-expressed CD62L ECD-Fc) |
| Small Molecule Inhibitors | Pharmaceutical Developers | Acute Inflammatory Disorders, Ischemia-Reperfusion | Selectivity profiling (Need CD62L, CD62P, and CD62E recombinant protein panel) |